The US Food and Drug Administration sees proactive surveillance of complex generics as a chance to avoid patient rejection of first generics in addition to monitor for any potential safety problems.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?